Working to Increase Vaccination for Human Papillomavirus: A Survey of Wisconsin Stakeholders, 2015

Sarah Mroz, MPH\textsuperscript{1,2}; Xiao Zhang, PhD\textsuperscript{1,3}; Mercedes Williams, BS\textsuperscript{4}; Amy Conlon, MPH\textsuperscript{1,2}; Noelle K. LoConte, MD\textsuperscript{1,2}

PEER REVIEWED

Abstract

Introduction
Infection with human papillomavirus (HPV) is common and can progress to various types of cancer. HPV infection can be prevented through vaccination; however, vaccination rates among adolescents are low. The objective of this study was to assess efforts among Wisconsin stakeholders in HPV vaccination and organizational capacity for future collaborative work.

Methods
We conducted a cross-sectional online survey of 277 stakeholders in HPV vaccination activities, from April 30, 2015, through June 30, 2015. Stakeholders were public health professionals, health care providers, educators, quality improvement professionals, researchers, and advocates identified as engaged in HPV vaccination work.

Results
Of the 277 invited stakeholders, 117 (42\%) responded to the survey. Findings showed that most current HPV vaccination activities targeted 3 groups: adolescents and parents, clinical and health professionals, and communities and health systems. The main activities directed at these groups were providing printed educational materials, professional education, and media campaigns to raise awareness. Common barriers reported were lack of understanding about the link between HPV and cancer, requests to delay vaccination, difficulty completing the 3-dose vaccine series, and reluctance to discuss sexuality.

Conclusion
HPV vaccination rates are far below those of other vaccinations administered to adolescents in Wisconsin. Our study showed that various local efforts were being made to increase HPV vaccination uptake; however, many barriers exist to initiation and completion of the vaccine series. Future interventions should address barriers and employ evidence-based strategies for increasing HPV vaccination rates.

Introduction
Human papillomavirus (HPV) infection is common, especially among young adults (1–3). Almost all cervical and anal cancers and most oropharyngeal cancers are caused by persistent infection with high-risk HPV, types 16 and 18 (4–6). HPV vaccines offer the best protection to women and men who receive all 3 doses in the series and have time to develop an immune response before becoming sexually active. Initiation of HPV vaccination is recommended for girls and boys beginning when they are aged 11 to 12 years (6). It is also recommended for girls aged 13 to 26 and for boys aged 13 to 21 who have not been vaccinated (7–9). However, since licensure of the first HPV vaccine in 2006, vaccination rates have remained low in the United States compared with rates for other adolescent vaccinations. In Wisconsin, data from the Wisconsin Immunization Registry indicate that HPV vaccination coverage is far lower than for other vaccines administered to adolescents. In 2013, an estimated 55\% of girls and 29\% of boys aged 13 to 17 had initiated the HPV vaccine series, and only 34\% of girls and 11\% of boys aged 13 to 17 had completed the series. By comparison, 92\% of adolescents in this age group have received the tetanus, diphtheria, pertussis (Tdap) vaccine, and 75\% had received the meningococcal conjugate vaccine (10).
The Wisconsin Comprehensive Cancer Control Program, housed at the University of Wisconsin Carbone Cancer Center, was among 18 sites funded by the National Cancer Institute to conduct an environmental scan of HPV vaccination activities to enhance collaborations for developing research and interventions to increase HPV vaccination rates in Wisconsin (11). The scan involved 4 components: 1) examination of vaccination data from the Wisconsin Immunization Registry, 2) a survey of stakeholders’ HPV-related projects, 3) assessment of current University of Wisconsin–Madison research on HPV, and 4) evaluation of a quality improvement education series for health care providers. The objective of this study was to assess local interventions to increase HPV vaccination and organizational capacity for future collaborative work in Wisconsin.

Methods

Study population

We conducted a cross-sectional online survey of 277 Wisconsin stakeholders in HPV vaccination activities from April 30, 2015, through June 30, 2015 (Appendix). Stakeholders were public health professionals, health care providers, educators, quality improvement professionals, researchers, and advocates from the state who attended or were invited to the Wisconsin HPV Vaccine Summit in June of 2014. The summit was a conference designed to mobilize vaccine advocates by providing data on state-specific HPV disease epidemiology and immunization rates, updates on the diseases caused by HPV, vaccine safety information, and discussions on how to address vaccination hesitancy and strengthen vaccination recommendations. We also surveyed members of the 15 local or regional immunization coalitions in Wisconsin. Stakeholders received an email inviting them to participate in the online survey. Four follow-up email reminders were sent to incomplete survey respondents and nonrespondents at intervals of every 2 weeks to encourage participation.

Measures

Study participants reported on their role in their organization and answered other organization-related questions, including type of organization, whether the organization belonged to a local or regional immunization coalition, whether the organization accessed the Wisconsin Immunization Registry, and whether the organization used the Registry for Effectively Communicating Immunization Needs and an electronic health record to track immunizations. Respondents were also asked about their organization’s interest in conducting new activities and their capacity to take on new activities to promote HPV vaccination.

Respondents were asked whether their organizations conducted any activities in Wisconsin in 2013, 2014, or 2015 related to HPV vaccination. The activities were classified into 4 categories: 1) adolescents and their parents, 2) clinical and health care professionals, 3) communities and health systems, and 4) advocacy and public policy. If respondents reported activities in any year in any of these categories, they were asked to provide information about how often they encountered certain barriers (never, rarely, sometimes, often, or always). The selections of sometimes, often, and always were defined as barriers. In addition, respondents provided information on their funding sources and collaborating organizations for each category of activities.

Statistical analysis

We calculated simple descriptive statistics to examine the prevalence of HPV vaccination-related activities that stakeholders conducted from 2013 through 2015 and the barriers they encountered. We then tested for trends in different activities over time. All analyses were performed with Stata/MP version 13.1 (StataCorp LP). Significance was set at \( P \) less than .05.

Results

Of the 277 stakeholders we invited to participate, 117 replied, a response rate of 42.2%. Of the 117 stakeholders who participated in the survey, 37 (31.6%) classified themselves as public health professionals, 21 (17.9%) as health care providers, and 9 (7.7%) as educators (Table). Thirty (25.6%) of the respondents worked for local public health departments, 8 (6.8%) worked for state health departments, and 22 (18.8%) for health care providers/health systems (categories were not mutually exclusive). Fifty-six (47.9%) indicated that they or their organization belonged to a local or regional immunization coalition, 71 (60.7%) reported that their organizations currently accessed the Wisconsin Immunization Registry, 6 (5.1%) used the Regional Early Childhood Immunization Network, and 32 (27.4%) used an electronic health record to track immunizations. Over half of respondents 67 (57.3%) expressed a medium to high level of interest in conducting new activities to promote HPV vaccination. However, only 46 (39.3%) rated their capacity to take on new activities as adequate (medium or high capacity).

Stakeholders reported on activities that their organizations conducted in recent years to increase HPV vaccination. Ninety-four (80.3%) reported that their organizations were involved in activities focusing on adolescents (girls or boys aged 11–18 y) and their parents. In 2015, the most common activities involving adolescents and their parents were providing printed educational materials (69.2%), one-on-one consultations to adolescents and parents on HPV vaccination (54.7%), reminders to adolescents and par-
ents of when adolescents were due for HPV vaccination (47.9%), and referrals to HPV vaccination services (46.2%). The pattern was similar for 2013 and 2014, and the prevalence of these 4 types of activities increased significantly over time ($P < .05$) (Figure 1a).
Figures 1a–d. Percentage of Wisconsin stakeholder organizations (N = 117) reporting activities to increase human papillomavirus vaccination in Wisconsin, 2013–2015. Figure 1a shows stakeholder organizations with activities focused on adolescents and parents, 1b shows stakeholder organizations with activities focused on clinical and health professionals, 1c shows stakeholder organizations with activities focused on communities and health systems, and 1d shows stakeholder organizations with activities focused on advocacy and public policy. The rates of advocating for public policy change and advocating for increased public funding increased over time (P < .05).

Overall, 75 respondents reported barriers to activities focusing on adolescents and parents. The most common barriers were lack of education or understanding about HPV infection, including its link to cancer (86.6%); logistical or other barriers to returning for the full series of 3 shots (74.7%); requests that HPV vaccination be deferred (71.7%); belief that the adolescent is not at risk for HPV infection (71.6%); and the parent’s belief that child is too young for the HPV vaccine (68.5%, Figure 2).
Seventy-six of the 117 respondents (65.0%) indicated that their organizations were conducting activities focusing on clinical and health professionals to increase HPV vaccination. The most commonly reported activities in 2015 were providing printed educational materials (53.0% of stakeholders), professional education on HPV vaccination (47.0%), protocols to track and report on HPV vaccination rates (35.0%), and websites focused on health professionals (11.1%) (Figure 1b). The increase in all activity rates from 2013 to 2015 was significant ($P < .05$). Barriers most often encountered by these organizations (N = 54) were difficulty ensuring that patients completed the 3-dose HPV vaccination series (63.0%), concern that parents would decline HPV vaccination despite appropriate counseling (57.7%), reluctance to discuss sexuality or sexually transmitted infections (45.3%), concern about the time it takes to discuss HPV vaccination with patients or parents (41.5%), and HPV vaccination not being required by schools (37.1%) (Figure 2b).

Sixty-one stakeholders (52.1%) identified their organization’s activities as projects focusing on communities and health systems. The most commonly reported activity in this category in 2015 was media campaigns to raise awareness about the need for HPV vaccination of adolescents (39.3%), followed by community committee or work groups that focus on HPV vaccination (24.8%), support for community groups that fund and promote the vaccine (23.1%), and community events or health fairs to promote HPV vaccination (21.4%) (Figure 1c). The increase from 2013 through 2015 in these activities was significant ($P < .05$). Barriers experienced in implementing community- and health-system–focused activities (N = 43) were lack of education or understanding about HPV infection, including its link to cancer (44.1%); difficulty ensuring that patients will complete the 3-dose HPV vaccination series (41.9%); belief that younger adolescents are too young for the HPV vaccinations (41.8%); and reluctance to discuss sexuality or sexually transmitted infections (38.7%) (Figure 2c).

Lastly, 18 respondents (15.4%) indicated that they were involved in activities focused on advocacy and public policy with the most commonly reported activity in 2015 being efforts to increase HPV vaccination rates through advocating public policy change (17 respondents), followed by advocating for increasing public funding for HPV vaccination (13 respondents) and advocating for increased public funding for HPV research (5 respondents) (categories were not mutually exclusive). The rates of the former 2 activities increased over time ($P < .05$) (Figure 1d). Barriers to these activities that respondents (N = 10) reported were described as lack of provider recommendations for HPV vaccination (7 respondents), concerns about vaccine safety (6 respondents), and reluctance to discuss sexuality or sexually transmitted infections (6 respondents) (Figure 2d).

Most organizations reported working with partners on activities promoting HPV vaccination: activities that focused on adolescents and parents (50 of 94 respondents), activities that focused on clinical and health professionals (47 of 76 respondents), activities that focused on communities and health systems (37 of 61 respondents), and activities that focused on advocacy and public policy (14 of 18 respondents). Commonly reported collaborators were the Centers for Disease Control and Prevention (CDC), the Wisconsin Immunization Program, local health departments, local clinics and hospitals, schools, local immunization coalitions, the Wisconsin Comprehensive Cancer Control Program, and the Wisconsin chapter of the American Academy of Pediatrics. Primary sources of funding for HPV vaccination activities were CDC, the Wisconsin chapter of the American Academy of Pediatrics, the Wisconsin Department of Health Services, the University of Wisconsin Partnership Program, the Wisconsin Immunization Program, immunization coalitions, the Wisconsin Comprehensive Cancer Control Program, and tax levy funds.

Discussion

Persistent HPV infection can lead to cancer of the cervix, vulva, vagina, penis, anus, and oropharynx (12). The HPV vaccine is safe and effective and has been recommended since 2006 (13). However, HPV vaccination coverage has remained far below that of other vaccinations administered to adolescents, in Wisconsin and throughout the United States. To assess efforts to increase HPV vaccination in Wisconsin and barriers encountered, we conducted a survey of stakeholders involved in the effort. Findings from the survey illustrate the HPV vaccination-related projects being conducted in Wisconsin and provide a roadmap for future collaboration and activities to increase HPV vaccination. Our survey of stakeholder activities found that ongoing work is focused on 4 main groups: adolescents and parents, clinical and health professionals, communities and health systems, and stakeholders in-
volved with advocacy and public policy. HPV vaccination promo-
tion activities increased across all these groups from 2013 through
2015. Many survey respondents reported conducting activities that
were focused on adolescents and parents, the most common of
which were the provision of educational materials, one-on-one
consultations and referrals, and reminders for vaccination. The
main activities used to influence clinical and health professionals
were provision of educational materials, professional education,
and protocols to track and report vaccination rates. These activi-
ties are in line with research, which indicates that educational cam-
paigns directed at health care professionals and parents are key fa-
cilitators for promoting HPV vaccination (14). Examples of educa-
tional efforts to raise awareness about HPV and HPV vaccination
are media campaigns, printed materials, online information, web-
inars, conferences, and in-person training sessions. Of the activi-
ties designed to affect communities and health systems, media
campaigns to raise awareness were used most often, followed by
health fairs and community group collaborations. We identified
fewer activities in the area of advocacy and public policy, but
among the activities reported were advocating for public policy
change and advocating for increased public funding for vaccina-
tion. HPV vaccination promotion activities in Wisconsin are simi-
lar to efforts conducted at the health care practice or community
level in other parts of the United States. The effectiveness of inter-
ventions to increase HPV vaccination has varied, and further re-
search is needed (15–17).

As in other research, Wisconsin stakeholders reported several
main barriers to vaccination across groups: lack of understanding
about HPV and its link to cancer, reluctance to discuss sexuality,
parental resistance to the vaccination, belief that the adolescent is
too young or is not at risk, difficulty with completion of the 3-dose
vaccine series, safety concerns, and concern about promoting risky
sexual behavior (3,18,19). Health care providers have been identi-
fied as uniquely positioned to address barriers perceived by par-
ents. They can initiate conversations to address concerns and mis-
understandings and recommend the vaccine (19). Studies have
shown that parents and patients want additional information about
HPV and the HPV vaccine and that they trust the information
provided by health care providers (20). Providers need additional
training on how to give a strong, clear recommendation and com-
municate the urgency and importance of HPV vaccination (14).
Other potential strategies for providers and health care systems to
increase HPV vaccination rates are reducing missed clinical op-
portunities and administering the HPV vaccine at the same time as
other adolescent vaccines (18). To reduce the number of HPV-re-
lated cancer deaths in Wisconsin and reach the Healthy People
2020 goal of 80% HPV vaccination coverage, continued efforts
are needed to cultivate provider champions for the vaccine, edu-
cate the public about its safety and efficacy, increase access to
vaccination, and reduce missed clinical opportunities to vaccinate
(21). The consistency of barriers cited across target groups related
to the lack of understanding about HPV, the HPV vaccine, and
HPV related cancers indicates that future efforts should focus on
enhanced education and communication strategies for providers,
parents, adolescents, and communities. The Advisory Committee
on Immunization Practices recommends that young adolescents
(aged 9–14 y) move from a 3-dose to a 2-dose HPV vaccine
schedule (22,23). This change presents new opportunities for in-
creasing adherence. The change, also recommended by CDC, was
based on a review of clinical trials showing that 2 doses of the
vaccine among young adolescents produced an immune response
similar to, or higher than, the response in young adults (aged
16–26 y) who received 3 doses (24). Because survey respondents
cited logistical challenges to returning for the series of 3 shots as a
barrier, the move to a 2-dose schedule — which still provides safe,
long lasting, effective protection — may increase acceptance and
improve vaccination rates among young adolescents (23). More
than half of survey respondents expressed interest in conducting
new activities to promote HPV vaccination. However, because
less than 40% said they had the organizational capacity to do so,
policy efforts should focus on increasing funding for HPV vaccin-
ation education and promotion. HPV vaccination rates in Wiscon-
sin have increased in recent years. In 2015, the overall vaccina-
tion rate for adolescents aged 13 to 18 years was 44%, and in 2016
the rate was 49% (https://www.dhs.wisconsin.gov/immunization/
data.htm).

A strength of our study is that it is the first statewide, comprehens-
ive review of HPV vaccination activities in Wisconsin. A limita-
tion is that our list of Wisconsin HPV vaccination stakeholders
may be incomplete, and we do not have information about HPV
vaccination-related activities conducted by stakeholders who were
not identified. However, the participant list was reviewed by rep-
resentatives of the Wisconsin Immunization Program, the Wiscon-
sin chapter of the American Academy of Pediatrics, and the Uni-
versity of Wisconsin Immunization Taskforce to identify missing
stakeholders engaged in current or recent HPV vaccination work
who were then added to the group. Another limitation is that the
survey response rate was moderate (42.2%), but it was within the
range (40%–60%) recommended for surveys to inform key
policies and resource allocation (24). A comparison between sur-
vey respondents and nonrespondents indicated that the geographic
distribution was similar between the 2 groups, suggesting that the
survey findings were representative of the state. The Wisconsin
HPV stakeholder survey found that activities promoting HPV vac-
cination are wide-ranging and have increased over time across the
state. Future interventions should address identified barriers and
employ evidence-based strategies for increasing HPV vaccination
rates.
Acknowledgments

Funding for the Wisconsin Comprehensive Cancer Control Program’s stakeholder survey was provided by the National Cancer Institute grant no. 3P30CA014520-40S3.

Author Information

Corresponding Author: Noelle K. LoConte, MD, University of Wisconsin Carbone Cancer Center, 600 Highland Ave, CSC K4/548, Madison, WI 53792. Telephone: 608-265-5883. Email: ns3@medicine.wisc.edu.

Author Affiliations: 1University of Wisconsin Carbone Cancer Center, Madison, Wisconsin. 2Wisconsin Comprehensive Cancer Control Program, Madison, Wisconsin. 3University of Wisconsin Cancer Prevention and Outcomes Data Shared Resource, Madison, Wisconsin. 4University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin.

References

1. Dunne EF, Nielson CM, Stone KM, Markowitz LE, Giuliano AR. Prevalence of HPV infection among men: a systematic review of the literature. J Infect Dis 2006;194(8):1044–57.
2. Dunne EF, Sternberg M, Markowitz LE, McQuillan G, Swan D, Patel S, et al. Human papillomavirus (HPV) 6, 11, 16, and 18 prevalence among females in the United States — National Health and Nutrition Examination Survey, 2003–2006: opportunity to measure HPV vaccine impact? J Infect Dis 2011;204(4):562–5.
3. Holman DM, Benard V, Roland KB, Watson M, Liddon N, Stokley S. Barriers to human papillomavirus vaccination among US adolescents: a systematic review of the literature. JAMA Pediatr 2014;168(1):76–82.
4. Centers for Disease Control and Prevention. Human papillomavirus-associated cancers — United States, 2004–2008. MMWR Morb Mortal Wkly Rep 2012;61(15):258–61.
5. Centers for Disease Control and Prevention. Human papillomavirus-associated cancers: how many cancers are linked with HPV each year? http://www.cdc.gov/cancer/hpv/statistics/cases.htm. Accessed May 5, 2014.
6. Centers for Disease Control and Prevention. HPV vaccine — questions and answers. http://www.cdc.gov/vaccines/vpd-vac/hpv/vac-faqs.htm. Accessed May 6, 2014.
7. Markowitz LE, Dunne EF, Saraiya M, Lawson HW, Chesson H, Unger ER; Centers for Disease Control and Prevention; Advisory Committee on Immunization Practices. Quadrivalent human papillomavirus: recommendations of the advisory committee on immunization practices (ACIP). MMWR Recomm Rep 2007;56(RR-2,RR02):1–24.
8. Centers for Disease Control and Prevention. Human papillomavirus vaccination coverage among adolescent girls, 2007–2012, and postlicensure vaccine safety monitoring, 2006–2013 — United States. MMWR Morb Mortal Wkly Rep 2013;62(29):591–5.
9. Centers for Disease Control and Prevention. Recommendations on the use of quadrivalent human papillomavirus vaccine in males — Advisory Committee on Immunization Practices (ACIP), 2011. MMWR Morb Mortal Wkly Rep 2011;60(50):1705–8.
10. Lazar KK, Imm P, Petit A, Conlon A, LoConte N. CCC issue brief: human papillomavirus (HPV) related cancers and vaccination coverage in Wisconsin. Madison (WI): Wisconsin Comprehensive Cancer Control Program; 2014. http://www.wicancer.org. Accessed July 22, 2014.
11. Wilburn A, Vanderpool RC, Knight JR. Environmental scanning as a public health tool: Kentucky’s Human Papillomavirus Vaccination Project. Prev Chronic Dis 2016;13:E109.
12. Centers for Disease Control and Prevention. Sexually transmitted diseases (STDs) — genital HPV infection fact sheet. 2013. http://www.cdc.gov/STD/HPV/STDFact-HPV.htm. Accessed May 6, 2014.
13. Centers for Disease Control and Prevention. HPV vaccine information for clinicians. https://www.cdc.gov/hpv/hcp/need-to-know.pdf. Accessed September 22, 2016.
14. Widman CA, Rodriguez EM, Saad-Harfouche F, Twarozek AM, Erwin DO, Mahoney MC. Clinician and parent perspectives on educational needs for increasing adolescent HPV vaccination. J Cancer Educ 2016.
15. Smulian EA, Mitchell KR, Stokley S. Interventions to increase HPV vaccination coverage: a systematic review. Hum Vaccin Immunother 2016;12(6):1566–88.
16. Niccolai LM, Hansen CE. Practice- and community-based interventions to increase human papillomavirus vaccine coverage: a systematic review. JAMA Pediatr 2015;169(7):686–92.
17. Fu LY, Bonhomme LA, Cooper SC, Joseph JG, Zimet GD. Educational interventions to increase HPV vaccination acceptance: a systematic review. Vaccine 2014;32(17):1901–20.
18. Reiter PL, Cates JR, McRee A-L, Gottlieb SL, Shafer A, Smith JS, et al. Statewide HPV vaccine initiation among adolescent females in North Carolina. Sex Transm Dis 2010; 37(9):549–56.

19. Brewer NT, Fazekas KI. Predictors of HPV vaccine acceptability: a theory-informed, systematic review. Prev Med 2007;45(2-3):107–14.

20. Zimet GD. Improving adolescent health: focus on HPV vaccine acceptance. J Adolesc Health 2005; 37(6,Suppl):S17–23.

21. Office of Disease Prevention and Health Promotion. Healthy people 2020. https://www.healthypeople.gov/2020/topics-objectives/national-snapshot/hpv-vaccine-adolescents-2008%E2%80%932012. Accessed August 17, 2016.

22. American Academy of Family Physicians. ACIP recommends two-dose regimen for HPV vaccine. http://www.aafp.org/news/health-of-the-public/20161026acipoctmtg.html. Accessed November 22, 2016.

23. Centers for Disease Control and Prevention. CDC recommends only two HPV shots for younger adolescents. http://www.cdc.gov/media/releases/2016/p1020-hpv-shots.html. Accessed November 22, 2016.

24. Best practices in public opinion research. Canada: public works and government services Canada. http://www.tpsgc.pwgsc.gc.ca/rop-por/rapports-reports/comitephonepanelplane/page-06-eng.html. Accessed April 25, 2014.
Table

Table. Characteristics of HPV Vaccination Stakeholders and Their Organizations in Wisconsin (N = 117)

| Characteristic                                                                 | No. (%) |
|-------------------------------------------------------------------------------|---------|
| **Position or role in organization**                                         |         |
| Public health professional                                                    | 37 (31.6) |
| Health care provider                                                          | 21 (17.9) |
| Educator                                                                      | 9 (7.7) |
| Advocate                                                                      | 6 (5.1) |
| Member of a community-based organization                                      | 7 (6.0) |
| Researcher/academic staff                                                     | 6 (5.1) |
| Other or unknown                                                              | 51 (43.6) |
| **Type of organization**                                                      |         |
| Local public health department                                                | 30 (25.6) |
| State public health department                                                | 8 (6.8) |
| Health care provider/health system                                            | 22 (18.8) |
| College or university                                                         | 11 (9.4) |
| Other or unknown                                                              | 50 (42.7) |
| **Belong to a local or regional immunization coalition**                     |         |
| Currently access the Wisconsin Immunization Registry                          | 71 (60.7) |
| Currently use the Regional Early Childhood Immunization Network to track immunizations | 6 (5.1) |
| Currently use an electronic health record to track immunization               | 32 (27.4) |
| **Interest level in conducting new activities to promote HPV vaccination**    |         |
| High                                                                          | 40 (34.2) |
| Medium                                                                        | 27 (23.1) |
| Low                                                                           | 8 (6.8) |
| No                                                                            | 3 (2.6) |
| Don’t know                                                                    | 39 (33.3) |
| **Capacity to take on new activities to promote HPV vaccination**             |         |
| High                                                                          | 7 (6.0) |
| Medium                                                                        | 39 (33.3) |
| Low                                                                           | 24 (20.5) |
| No                                                                            | 3 (2.6) |
| Don’t know                                                                    | 44 (37.6) |
| **Have at least one staff member serving as a lead for a project to increase HPV vaccination rates** | 55 (47.0) |

Abbreviation: HPV, human papillomavirus.

* Categories are not mutually exclusive.
Appendix. Stakeholder Survey

This appendix is available for download as a Microsoft Word document at

https://www.cdc.gov/pcd/issues/2017/docs/16_0610Appendix.docx. [DOCX – 33KB]